Role of mass drug administration in elimination of Plasmodium falciparum malaria : a consensus modelling study
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission.
METHODS: We collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration.
FINDINGS: The models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest.
INTERPRETATION: Mass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect.
FUNDING: Bill & Melinda Gates Foundation.
| Errataetall: |
CommentIn: Lancet Glob Health. 2017 Jul;5(7):e638-e639. - PMID 28619211 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
The Lancet. Global health - 5(2017), 7 vom: 15. Juli, Seite e680-e687 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brady, Oliver J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimalarials |
|---|
| Anmerkungen: |
Date Completed 02.04.2018 Date Revised 16.07.2022 published: Print-Electronic CommentIn: Lancet Glob Health. 2017 Jul;5(7):e638-e639. - PMID 28619211 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2214-109X(17)30220-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272469092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272469092 | ||
| 003 | DE-627 | ||
| 005 | 20231224234930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2214-109X(17)30220-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0908.xml |
| 035 | |a (DE-627)NLM272469092 | ||
| 035 | |a (NLM)28566213 | ||
| 035 | |a (PII)S2214-109X(17)30220-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brady, Oliver J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Role of mass drug administration in elimination of Plasmodium falciparum malaria |b a consensus modelling study |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2018 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Lancet Glob Health. 2017 Jul;5(7):e638-e639. - PMID 28619211 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Mass drug administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some settings. We used consensus modelling to understand how to optimise the effects of mass drug administration in areas with low malaria transmission | ||
| 520 | |a METHODS: We collaborated with researchers doing field trials to establish a standard intervention scenario and standard transmission setting, and we input these parameters into four previously published models. We then varied the number of rounds of mass drug administration, coverage, duration, timing, importation of infection, and pre-administration transmission levels. The outcome of interest was the percentage reduction in annual mean prevalence of P falciparum parasite rate as measured by PCR in the third year after the final round of mass drug administration | ||
| 520 | |a FINDINGS: The models predicted differing magnitude of the effects of mass drug administration, but consensus answers were reached for several factors. Mass drug administration was predicted to reduce transmission over a longer timescale than accounted for by the prophylactic effect alone. Percentage reduction in transmission was predicted to be higher and last longer at lower baseline transmission levels. Reduction in transmission resulting from mass drug administration was predicted to be temporary, and in the absence of scale-up of other interventions, such as vector control, transmission would return to pre-administration levels. The proportion of the population treated in a year was a key determinant of simulated effectiveness, irrespective of whether people are treated through high coverage in a single round or new individuals are reached by implementation of several rounds. Mass drug administration was predicted to be more effective if continued over 2 years rather than 1 year, and if done at the time of year when transmission is lowest | ||
| 520 | |a INTERPRETATION: Mass drug administration has the potential to reduce transmission for a limited time, but is not an effective replacement for existing vector control. Unless elimination is achieved, mass drug administration has to be repeated regularly for sustained effect | ||
| 520 | |a FUNDING: Bill & Melinda Gates Foundation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 700 | 1 | |a Slater, Hannah C |e verfasserin |4 aut | |
| 700 | 1 | |a Pemberton-Ross, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Wenger, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Maude, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Ghani, Azra C |e verfasserin |4 aut | |
| 700 | 1 | |a Penny, Melissa A |e verfasserin |4 aut | |
| 700 | 1 | |a Gerardin, Jaline |e verfasserin |4 aut | |
| 700 | 1 | |a White, Lisa J |e verfasserin |4 aut | |
| 700 | 1 | |a Chitnis, Nakul |e verfasserin |4 aut | |
| 700 | 1 | |a Aguas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Hay, Simon I |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Stuckey, Erin M |e verfasserin |4 aut | |
| 700 | 1 | |a Okiro, Emelda A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Okell, Lucy C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Global health |d 2013 |g 5(2017), 7 vom: 15. Juli, Seite e680-e687 |w (DE-627)NLM237515954 |x 2214-109X |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2017 |g number:7 |g day:15 |g month:07 |g pages:e680-e687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2214-109X(17)30220-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2017 |e 7 |b 15 |c 07 |h e680-e687 | ||